Application for Ibrutinib to preparation of drugs for resisting severe hepatitis

The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-mediated mouse severe hepatitis model is utilized to verify the inhibitory effect of Ibrutinib on liver functions and liver pathology; and endotoxin (LPS) is utilized to verify the anti-inflammatory effect of Ibrutinib at a cellular level. In-vitro and in-vivo experimental results prove that Ibrutinib has strong inhibitory effect on the occurence and development of the severe hepatitis. Meanwhile, Ibrutinib has a clear target and indications, is applicable to clinical practice, and can be used as a drug for the treatment of severe hepatitis. The invention provides the novel medical application of Ibrutinib, and Ibrutinib provides a novel means for treatment of severe hepatitis. 本发明的目的是提供依鲁替尼(Ibrutinib)在制备抗重症肝炎药物中的应